Cannabinoid and neurodegenerative
1: Gentile A, Fresegna D, Musella A, Sepman H, Bullitta S, De Vito F, Fantozzi R, Usiello A, Maccarrone M, Mercuri NB, Lutz B, Mandolesi G, Centonze D. Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis. J Neuroinflammation.
2: Jayant S, Sharma B. Selective modulator of cannabinoid receptor type 2 reduces memory impairment and infarct size during cerebral hypoperfusion and vascular dementia. Curr Neurovasc Res.
3: Tomas-Roig J, Benito E, Agis-Balboa RC, Piscitelli F, Hoyer-Fender S, Di Marzo V, Havemann-Reinecke U. Chronic exposure to cannabinoids during adolescence causes long-lasting behavioral deficits in adult mice. Addict Biol.
4: Chung YC, Shin WH, Baek JY, Cho EJ, Baik HH, Kim SR, Won SY, Jin BK. CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.
5: Javed H, Azimullah S, Haque ME, Ojha SK. Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease. Front Neurosci.
National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).